Ionis Pharmaceuticals, Inc. ranks below the peer group median, with growth as the main structural strength, while profitability is less supportive than the other dimensions.
Peer-relative scores, weakest to strongest
Ionis Pharmaceuticals develops RNA-targeted therapies for rare and chronic diseases, focusing on innovative drug discovery and commercialization.
The premium reflects pipeline speed, not operational quality. With revenue growth at 87% year-on-year, IONS attracts attention for its rapid product launches, but an operating margin of -24% indicates profitability is significantly behind the pace of expansion. Because IONS pursues independent commercialization and accelerates its RNA therapeutics pipeline, the market instantly prices in every pipeline update as a signal of future growth, and reacts to any negative surprise with immediate valuation pressure. The market prices in pipeline progress instantly, while persistent margin weakness receives less attention. The market compresses the premium abruptly in response to any single setback in pipeline launches.
Break down IONS's position across all dimensions with the full interactive tool.
This analysis is rule-based and descriptive. Peer-relative scores are derived from functional peer group comparisons using publicly available financial data. Scores reflect structural positioning only and do not constitute investment advice, a buy or sell recommendation, or a forecast of future performance. AssetNext peer scores are recalculated periodically as new data becomes available.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.